A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2004
11/03/2004	EP1083899A4 Method of enhancing lysosomal alpha-galactosidase a
11/03/2004	EP1047709B1 Compounds with growth hormone releasing properties
11/03/2004	EP0989850B1 Use of pramipexole in the treatment of restless legs syndrome
11/03/2004	EP0942906B1 Compounds useful for inhibition of farnesyl protein transferase
11/03/2004	EP0729325B1 Osteogenic product and use
11/03/2004	EP0722324B1 Pharmaceutical composition for immunoenhancement therapy
11/03/2004	EP0694042B1 Inhibitor of vascular endothelial cell growth factor
11/03/2004	CN1543504A 疫苗 Vaccine
11/03/2004	CN1543476A Methods and compounds for the targeting of protein to exosomes
11/03/2004	CN1543475A Novel genetic products from ashbya gossypii, associated withthe structure of the cell wall or the cytoskeleton
11/03/2004	CN1543473A Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds
11/03/2004	CN1543467A Diazacycloalkanes as oxytocin agonists
11/03/2004	CN1543466A New use of specific cyclolignans
11/03/2004	CN1543464A Novel imidazopyridine compounds with therapeutic effect
11/03/2004	CN1543462A Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof
11/03/2004	CN1543456A Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
11/03/2004	CN1543358A Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
11/03/2004	CN1543351A Method for enhancing the effectiveness of cancer therapies
11/03/2004	CN1543349A Enhanced drug delivery in transdermal systems
11/03/2004	CN1543347A Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
11/03/2004	CN1543346A Novel compounds
11/03/2004	CN1543345A Methods for selective immunomodulation using pimecrolimus
11/03/2004	CN1543338A Chitin microparticles and their medical uses
11/03/2004	CN1542010A Azolo triazines and pyrimidines
11/03/2004	CN1542002A Inhibitors of metalloproteinase, pharmaceutical compositions containing them, their pharmaceutical application and methods and intermediate compounds for their preparation
11/03/2004	CN1542001A Small molecule inhibitors of rotamase enzyme activity
11/03/2004	CN1541706A Inhibitor and stimulator of stem cell proliferation and uses thereof
11/03/2004	CN1541704A Osteoprosis treating medicament and osteoclast creating inhibitor
11/03/2004	CN1174094C Inhibitors of cellulolytic, xylanolytic and beta-glucanolytic enzymes
11/03/2004	CN1173975C Imidazopyridine derivatives
11/03/2004	CN1173974C Piperidylaminomethyltrifluoromethyl cyclic ether compound as p substance antagonist
11/03/2004	CN1173970C Tetrahydroquinoline derivatives as glycine antagonists
11/03/2004	CN1173969C Novel lipoic acid derivatives, their preparation method and medical use, and pharmaceutical compositions containing them
11/03/2004	CN1173964C Novel benzofuranone derivative and process for producing same
11/03/2004	CN1173957C Substituted piperazones and their therapeutic use
11/03/2004	CN1173950C 2,3-Disubstituted pyridine derivatives, process for preparation thereof, drug compositions containing the same and intermediates for preparation
11/03/2004	CN1173948C Alpha-substituted arylsulphonamido hydroxamic acids as TNF-alpha and matrix metalloproteinase inhibitors
11/03/2004	CN1173741C Concatenated antidiotype monoclonic antibody vaccine for fish diseases
11/03/2004	CN1173735C Use of anti-gp 39 antibodies for treatment and/or reversal of lupus and associated kidney disease
11/03/2004	CN1173728C Medicine for delaying senility and its preparing process
11/03/2004	CN1173718C Medicine for curing rheumatism arising from immune diease lupus erythematosus
11/03/2004	CN1173715C Medicine pill for preventing and treating pathological senility
11/03/2004	CN1173710C Treatment of congestive heart failure by pretreated autologous blood
11/03/2004	CN1173695C Controlled release and odor masking oral pharmaceutical compositions
11/03/2004	CN1173694C Pharmaceutical composition for treatment of acute disorders
11/02/2004	US6812364 Central nervous system disorders; psychological disorders; anticancer agents
11/02/2004	US6812258 Cancer treatment composition and method using natural plant essential oils
11/02/2004	US6812253 4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical
11/02/2004	US6812250 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments
11/02/2004	US6812235 2-acylamino- beta -alanine derivatives and a pharmaceutically acceptable salt, useful as fibrinogen receptor antagonists
11/02/2004	US6812225 Pyschological disorders; antidepressants
11/02/2004	US6812219 Methods and compositions for treating flaviviruses and pestiviruses
11/02/2004	US6812214 Use of harpagid-related compounds for prevention and treatment of osteoporosis, arthritis and ruptured disc and pharmaceutical composition containing the same
11/02/2004	US6812213 Steroidal sapogenins and their derivatives for treating alzheimer's disease
11/02/2004	US6812210 Urocortin-III and uses thereof
11/02/2004	US6812203 Treatment of cd40 and/or nf-kb related diseases, antiinflammatory, antitumor
11/02/2004	US6812037 Antimitotic compounds
11/02/2004	US6812025 Detection of preferential enzyme inhibitors; obtain sample containing enzyme, incubate with modulator and nucleotide sequences, monitor amplification of preferential nucleotide sequences, absence of sequences indicates modulator
11/02/2004	US6811779 Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
11/02/2004	CA2338704C Oral liquid mucoadhesive compositions
11/02/2004	CA2317736C Bisulfate salt of hiv protease inhibitor
11/02/2004	CA2301787C New derivatives of benzo[3,4]cyclobuta[1,2-c]pyrrole, the procedure for preparing them and the pharmaceutical compounds that contain them
11/02/2004	CA2296970C Neuropeptide y antagonists
11/02/2004	CA2282279C Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
11/02/2004	CA2129040C Styryl derivatives and processes for their preparation
11/02/2004	CA2115536C Heterocyclically substituted phenyl-cyclohexane-carboxylic acid derivatives
11/02/2004	CA2111100C Interleukin-1 beta protease and interleukin-1 beta protease inhibitors
11/02/2004	CA2094806C Aminosulfonyl urea acat inhibitors
10/2004
10/28/2004	WO2004092388A1 Vector
10/28/2004	WO2004092374A1 METHOD OF REGULATING ACTIVATION OF TRANSCRIPTIONAL FACTORS NF-AT, AP-1 AND NF-κB USING EFFECT OF ACTIVATING ADAPTOR PROTEIN 3BP2
10/28/2004	WO2004092223A1 Cross-linked polysaccharide composition
10/28/2004	WO2004092199A2 Method for identifying modulators of g protein coupled receptor signaling
10/28/2004	WO2004092169A1 Spiropiperidine compound and medicinal use thereof
10/28/2004	WO2004092153A1 Diamine derivative, production process, and antioxidizing drug
10/28/2004	WO2004092136A1 Nitrogenous heterocyclic compound and use thereof
10/28/2004	WO2004091659A1 Drug for preventing or treating angiogenic eye diseases
10/28/2004	WO2004091643A1 Agent for increasing granulocyte macrophage colony stimulating factor
10/28/2004	WO2004091628A1 Receptor antagonist
10/28/2004	WO2004091599A1 Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol
10/28/2004	WO2004091598A1 Use of beta-aminoisobutyric acid for the treatment of diseases linked to the accumulation of triglycerides and cholesterol
10/28/2004	WO2004091592A2 Methods and compositions to treat myocardial conditions
10/28/2004	WO2004062555A3 Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
10/28/2004	WO2004004648A3 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
10/28/2004	WO2003095613A3 Nucleic acids, polypeptides, and methods for modulating apoptosis
10/28/2004	WO2003030833A3 Angiopoietin-2 specific binding agents
10/28/2004	WO2003026591A3 Modification of feeding behavior
10/28/2004	WO2003022882A3 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
10/28/2004	WO2003018515A3 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
10/28/2004	WO2002088322A3 Cell adhesion and extracellular matrix proteins
10/28/2004	WO2001039723A3 Triazospiro compounds having nociceptin receptor affinity
10/28/2004	US20040215023 Crystal and process for producing the same
10/28/2004	US20040215018 use as selective estrogen receptor modulators, and use in inhibiting bone loss, cardiovascular disease, and breast and uterine carcinoma
10/28/2004	US20040215017 Such as 2-methylpropyl-(4-bromo-3-fluorophenyl)carbamate
10/28/2004	US20040215014 Auroyl cyclic amines for controlling behavior or appetite
10/28/2004	US20040214902 Small molecule antagonists of BCL-2 family proteins
10/28/2004	US20040214896 drugs and/or prodrugs such as N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide, used for prophylaxis of inflammatory disorders, cancers, psoriasis, diabetes, autoimmune diseases, hepatitis, graft versus host disease or endometriosis
10/28/2004	US20040214890 1,3-diamino-2-hydroxypropane derivatives are useful as inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal
10/28/2004	US20040214888 Carboxylic acid derivative and medicine comprising salt or ester of the same
10/28/2004	US20040214877 Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors
10/28/2004	US20040214875 Imidazolinylmethyl aralkylsulfonamides

1 ... 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 ... 1564